In addition, clinical data suggest that even if patients with PC enter the CRPC stage, the androgen signaling pathway still plays an important role in the progression of PC, and the antitumor efficacy of DTX in CRPC could be improved by inhibition of AR-pathway signaling [9,10]. The gene discussed is AR; the disease is pachyonychia congenita.